Products Categories
CAS No.: | 5536-17-4 |
---|---|
Name: | vidarabine |
Article Data: | 57 |
Molecular Structure: | |
Formula: | C10H13N5O4 |
Molecular Weight: | 267.244 |
Synonyms: | Adenine,9-beta-D-arabinofuranosyl- (7CI,8CI);6-Amino-9-beta-D-arabinofuranosylpurine;9-Arabinosyladenine;9-beta-D-Arabinoadenosine;9-beta-D-Arabinofuranosyl-9H-purin-6-amine;9-beta-D-Arabinofuranosyladenine;Adenine 9-beta-D-arabinofuranoside;Adeninearabinoside;Adenine beta-D-arabinofuranoside;Araadenosine;Arabinosyladenine;Arasena-A;CI-673;NSC 247519;NSC 404241;Spongoadenosine;Vira-A;beta-Ara-A;beta-D-Arabinofuranosyladenine;beta-D-Arabinosyladenine; |
EINECS: | 226-893-9 |
Density: | 2.08 g/cm3 |
Melting Point: | 260-265 °C (dec.) |
Boiling Point: | 676.3 °C at 760 mmHg |
Flash Point: | 362.8 °C |
Solubility: | Insoluble in water |
Appearance: | white to off-white crystalline powder |
Hazard Symbols: | Xn,Xi |
Risk Codes: | 63-36/37/38 |
Safety: | 36/37-36-26 |
PSA: | 139.54000 |
LogP: | -1.39880 |
The Vidarabine anhydrous, with the CAS registry number 5536-17-4, is also known as Adenine-beta-D-arabinofuranoside. It belongs to the product category of Active Pharmaceutical Ingredients. Its EINECS registry number is 226-893-9. This chemical's molecular formula is C10H13N5O4 and molecular weight is 267.24. Its IUPAC name is called (2R,3S,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol. What's more, this chemical's classification codes are Anti-Infective Agents; Antimetabolites; Antiviral agents; Drug / Therapeutic Agent; Human Data; Mutation Data; Noxae; Reproductive Effect; Skin / Eye Irritant.
Physical properties of Vidarabine anhydrous: (1)ACD/LogP: -1.03; (2)# of Rule of 5 Violations: 1; (3)ACD/LogD (pH 5.5): -1.03; (4)ACD/LogD (pH 7.4): -1.02; (5)ACD/BCF (pH 5.5): 1; (6)ACD/BCF (pH 7.4): 1; (7)ACD/KOC (pH 5.5): 6.52; (8)ACD/KOC (pH 7.4): 6.6; (9)#H bond acceptors: 9; (10)#H bond donors: 5; (11)#Freely Rotating Bonds: 5; (12)Index of Refraction: 1.907; (13)Molar Refractivity: 59.95 cm3; (14)Molar Volume: 128.1 cm3; (15)Surface Tension: 107.6 dyne/cm; (16)Density: 2.08 g/cm3; (17)Flash Point: 362.8 °C; (18)Enthalpy of Vaporization: 104.3 kJ/mol; (19)Boiling Point: 676.3 °C at 760 mmHg; (20)Vapour Pressure: 3.26E-19 mmHg at 25°C.
Preparation of Vidarabine anhydrous: this chemical can be prepared by 1-(6-amino-purin-9-yl)-O2,O3,O5-tribenzyl-beta-D-1-deoxy-arabinofuranose. This reaction will need reagent Cyclohexene and solvent ethanol. The reaction time is 2 hours. The yield is about 98%.
Uses of Vidarabine anhydrous: it can be used to produce O2,O3,O5-triacetyl-1-(6-amino-purin-9-yl)-beta-D-1-deoxy-arabinofuranose. This reaction will need reagent pyridine. The yield is about 94%.
Vidarabine anhydrous is good for Herpes simplex virus (HSV-1 and HSV-2). In addition, this chemical not only can be used in the treatment of herpes simplex viral meningitis, but also in immunosuppressing patient's herpes zoster and varicella infections. When daily dose above 10mg/kg, you may appear anorexia, nausea, vomiting, diarrhea, transaminase lifts, dizziness, weakness, etc.
When you are using this chemical, please be cautious about it as the following:
This chemical may cause inflammation to the skin or other mucous membranes. It is irritating to eyes, respiratory system and skin. In case of contact with eyes, you should rinse immediately with plenty of water and seek medical advice. Whenever you will contact it, please wear suitable protective clothing and gloves.
You can still convert the following datas into molecular structure:
(1)Canonical SMILES: C1=NC2=C(C(=N1)N)N=CN2C3C(C(C(O3)CO)O)O
(2)Isomeric SMILES: C1=NC2=C(C(=N1)N)N=CN2[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O
(3)InChI: InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7+,10-/m1/s1
(4)InChIKey: OIRDTQYFTABQOQ-UHTZMRCNSA-N
The toxicity data is as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
human | TDLo | intravenous | 300ug/kg (0.3mg/kg) | BEHAVIORAL: ANOREXIA (HUMAN GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Journal of Infectious Diseases. Vol. 133, Pg. A192, 1976. |
human | TDLo | intravenous | 2mg/kg (2mg/kg) | BRAIN AND COVERINGS: CHANGES IN SURFACE EEG BEHAVIORAL: ATAXIA BEHAVIORAL: TOXIC PSYCHOSIS | Journal of Infectious Diseases. Vol. 134, Pg. 75, 1976. |
mouse | LD50 | intraperitoneal | 3057mg/kg (3057mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 15, Pg. 688, 1984. | |
mouse | LD50 | intravenous | 442mg/kg (442mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 15, Pg. 688, 1984. | |
mouse | LD50 | oral | 7800ug/kg (7.8mg/kg) | "Kirk-Othmer Encyclopedia of Chemical Technology," 3rd ed., Grayson, M., and D. Eckroth, eds. New York, John Wiley & Sons, Inc., 1978Vol. 2, Pg. 962, 1978. | |
mouse | LD50 | subcutaneous | 5086mg/kg (5086mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 15, Pg. 688, 1984. | |
rat | LD50 | intraperitoneal | 1476mg/kg (1476mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 15, Pg. 688, 1984. | |
rat | LD50 | intravenous | 302mg/kg (302mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 15, Pg. 688, 1984. | |
rat | LD50 | oral | > 5gm/kg (5000mg/kg) | LIVER: OTHER CHANGES | Annals of the New York Academy of Sciences. Vol. 284, Pg. 6, 1977. |
rat | LD50 | subcutaneous | 8914mg/kg (8914mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 15, Pg. 688, 1984. | |
women | LDLo | intravenous | 105mg/kg/1W-I (105mg/kg) | BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" BEHAVIORAL: TREMOR | Canadian Medical Association Journal. Vol. 132, Pg. 392, 1985. |